Pain and opioid use after reversal of sickle cell disease following HLA‐matched sibling haematopoietic stem cell transplant
Open Access
- 12 March 2018
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 184 (4) , 690-693
Abstract
No abstract availableKeywords
Funding Information
- National Heart, Lung, and Blood Institute
- National Center for Complementary and Integrative Health
- National Cancer Institute
- National Institutes of Health
This publication has 10 references indexed in Scilit:
- Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS® to ASCQ-Me℠Health and Quality of Life Outcomes, 2017
- AAPT Diagnostic Criteria for Chronic Sickle Cell Disease PainThe Journal of Pain, 2017
- Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantationBlood, 2017
- Chronic Opioid Therapy and Central Sensitization in Sickle Cell DiseaseAmerican Journal of Preventive Medicine, 2016
- An Evaluation of Central Sensitization in Patients With Sickle Cell DiseaseThe Journal of Pain, 2016
- Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell DiseaseTransplantation and Cellular Therapy, 2016
- Clinically Meaningful Interpretation of Pediatric Health-related Quality of Life in Sickle Cell DiseaseJournal of Pediatric Hematology/Oncology, 2015
- Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell PhenotypeJAMA, 2014
- Thinking beyond sickling to better understand pain in sickle cell diseaseEuropean Journal of Haematology, 2014
- The Patient-Reported Outcomes Measurement Information System (PROMIS)Medical Care, 2007